What we are studying
The purpose of this study is to see if Ocrelizumab (study drug) will halt the worsening of the signs and symptoms of early stage MS.
Compensation
You will be paid $1200.00 if you complete all the scheduled study visits. If you withdraw for any reason from the study before completion you will be paid $100.00 for each complete study visit.